ARTICLE | Product Development
Genmab’s strategy for going commercial
As Genmab moves toward commercialization, it plans to innovate the process
February 6, 2021 12:04 AM UTC
Genmab is preparing to join the expanding ranks of biotechs taking on commercialization, and CEO Jan van de Winkel is approaching commercial strategy with the same innovative eye he’s applied to development.
The company and partner Seagen Inc. (NASDAQ:SGEN) are planning to submit a BLA this quarter for first-in-class antibody-drug conjugate tisotumab vedotin, positioning the therapy for a 2021 decision. ...
BCIQ Company Profiles